Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Onida, Francesco ; de Wreede, Liesbeth C. ; van Biezen, Anja ; Eikema, Diderik-Jan ; Byrne, Jenny L. ; Iori, Anna P. ; Schots, Rik ; Jungova, Alexandra ; Schetelig, Johannes ; Finke, Jürgen ; Veelken, Hendrik ; Johansson, Jan-Erik ; Craddock, Charles ; Stelljes, Matthias ; Theobald, Matthias ; Holler, Ernst ; Schanz, Urs ; Schaap, Nicolaas ; Bittenbring, Jörg ; Olavarria, Eduardo ; Chalandon, Yves ; Kröger, Nicolaus

---

Alternative Links zum Volltext:DOIVerlag

---

Details

Dokumentenart:	Artikel
Titel eines Journals oder einer Zeitschrift:	British Journal of Haematology
Verlag:	WILEY
Ort der Veröffentlichung:	HOBOKEN
Band:	177
Nummer des Zeitschriftenheftes oder des Kapitels:	5
Seitenbereich:	S. 759-765
Datum:	2017
Institutionen:	Medizin > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Identifikationsnummer:	Wert Typ 10.1111/bjh.14619 DOI
Stichwörter / Keywords:	CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MUTATIONS; GENETICS; DISTINCT; CML; allogeneic transplantation; atypical chronic myeloid leukaemia; Myelodyslastic/Myeloproliferative Neoplasms (MDS/MPN); Ph-negative CML: BCR-ABL1-negative
Dewey-Dezimal-Klassifikation:	600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
Status:	Veröffentlicht
Begutachtet:	Ja, diese Version wurde begutachtet
An der Universität Regensburg entstanden:	Ja
Dokumenten-ID:	38946

Indiziert in

Web of Science

Bibliographische Daten exportieren

ASCII CitationAtomBibTeXData Cite XMLDataCite XML OAIDublin CoreDublin Core (LZV)EndNoteHTML CitationJSONJSON LDMETSMODSOPENAIREOpenAPCRDF+N-TriplesRDF+N3RDF+XMLReferReference ManagerSimple MetadataXMLxMetaDissPlus

---

Zusammenfassung

Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. ...

Zusammenfassung

Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.

---

---

Metadaten zuletzt geändert: 25 Nov 2020 15:45

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Altmetric

Altmetric

Altmetric

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)